Synthesis and antitumor activity of new thiosemicarbazones of 2-acetylimidazo[4,5-b]pyridine

Journal of Heterocyclic Chemistry

Volumn 42, Issue 7, 2005, Pages 1273-1281

  Mylonas, Stavros ^a   Mamalis, Athanasios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 ACETYLIMIDAZO[4,5 B]PYRIDINE 4 TERT BUTYL 3 THIOSEMICARBAZONE; 2 ACETYLIMIDAZO[4,5 E]PYRIDINE 4 TERT BUTYL 3 THIOSEMICARBAZONE; 2 ACETYLIMIDAZO[4,5 I]PYRIDINE 4 CYCLOHEXYL 3 THIOSEMICARBAZONE; NSC 674098; NSC 674099; NSC 674101; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; DNA SYNTHESIS INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INFRARED SPECTROSCOPY; LEUKEMIA; LYMPHOMA; PROSTATE CANCER; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

EID: 28244458437     PISSN: 0022152X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jhet.5570420705     Document Type: Article

References (21)

1. H. L. Elford, M. Freege E. Passamani and H. P. Morris, J. Biol. Chem., 245, 5228 (1970).
2. R. W. Brockman, J. R. Thomson, M. J. Beel and H. E. Skipper, Cancer Res., 6, 167 (1956).
3. F. A. French B. L. Freedlander Cancer Res., 18, 1290 (1958).
4. D. L. Klayman, J. P. Scovill, J. F. Barosevich and C. J. Mason, J. Med. Chem., 22, 1367-1373 (1979).
5. A. S. Dobek, D. L. Klayman, E. T. Dickson, J. P. Scovill and C. N. Oster, Arzneim-Forsch, 33(II), 1583 (1983).
6. C. Shipman, Jr., S. H. Smith, J. C. Drach and D. J. Klayman Antimicrob Agents Chemother, 19, 682 (1981).
7. J. Easmon, G. Heinisch, W. Holzer and B. Rosenwirth J. Med. Chem., 35, 3288 (1992).
8. B. R. Singh Talanta, 25, 619 (1978).
9. S. M. M. H. Majumder, Ali M. Akbar, F. Smith and M. A. U. Mridha Polyedron, 7, 2183 (1988).
10. T. Bamgboye and O. A. Bamgboye, Inorg Chim Acta, 105, 223 (1985).
11. H. G. Petering, H. H. Bustirk and J. A. Crim, Cancer Res., 27, 1115 (1967).
12. R. S. McElhinney J. Chem. Soc. (C), 950 (1966).
13. D. M. Livinstone Inorg Chim Acta, 19, 5 (1976).
14. J. A. Kiritsy and D. K. Yung J. Med. Chem., 21, 1301 (1978).
15. M. L. Moore and F. S. Crossley Organic Synthesis, Collective Vol. 3, 599.
16. J. C. Jochims Chem. Ber., 101, 1746 (1968).
17. M. R. Boyd, in Cancer: Principles and Practice of Oncology; V.T. De Vita Jr. S. Hellman and S.A. Rosenberg, Eds.; Lippincott: Philadelphia, PA, (1989); Vol. 3, pp 1-12.
18. M. R. Boyd, and K. D. Paul., Drug Development Research, 34, 91 (1995).
19. A. Monks, D. Scudiero, P. Skelian, R. Shoemaker, K. Paull, D. Vistico, D. Hose, J. Langler, P. Cronise, A. Vaigro-Wolf, M. Gray-Goodrich, H. Campoell and M. R. Boyd, J. Natl. Cancer Inst., 83, 757 (1991).
20. P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. McMahon, D. Vistica, J. Warren, H. Bokesh, S. Kenney and M. Boyd, J. Natl. Cancer Inst., 82, 1107 (1990).
21. K. D. Paul, Cancer Chemotherapeutic Agents. Chapter 2: Prediction of Biochemical Mechanism of Action from the in vitro Antitumour Screen of the National Cancer Institute; W. D. Foye ed. American Chemical Society, Washington D.C. 1995.